Page last updated: 2024-08-17

carbostyril and Progeria

carbostyril has been researched along with Progeria in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Avallone, H; Cao, K; Capell, BC; Chen, X; Collins, FS; Conneely, KN; Erdos, MR; Faddah, DA; Ganesh, SK; Kolodgie, FD; Nabel, EG; Olive, M; Qu, X; San, H; Tavarez, UL; Virmani, R	1
Bendale, P; Gelb, MH; Huyer, G; Mallampalli, MP; Michaelis, S	1

Other Studies

2 other study(ies) available for carbostyril and Progeria

Article	Year
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2008, Oct-14, Volume: 105, Issue:41 Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Mice; Progeria; Quinolones	2008
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2005, Oct-04, Volume: 102, Issue:40 Topics: Amino Acid Motifs; Blotting, Western; Cell Nucleus; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Lamin Type A; Lipoproteins; Membrane Proteins; Metalloendopeptidases; Metalloproteases; Mutation; Nuclear Proteins; Progeria; Protein Precursors; Protein Prenylation; Quinolones	2005

Article

Year

A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.

Proceedings of the National Academy of Sciences of the United States of America, 2008, Oct-14, Volume: 105, Issue:41

Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Mice; Progeria; Quinolones

2008

Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.

Proceedings of the National Academy of Sciences of the United States of America, 2005, Oct-04, Volume: 102, Issue:40

Topics: Amino Acid Motifs; Blotting, Western; Cell Nucleus; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Lamin Type A; Lipoproteins; Membrane Proteins; Metalloendopeptidases; Metalloproteases; Mutation; Nuclear Proteins; Progeria; Protein Precursors; Protein Prenylation; Quinolones

2005